2seventy bio, Inc.
DelistedCIK 1860782fmd_1P78X4VBJ8S265P5A0AYG84M26Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2025, 20 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Total revenues | 44 | 248 | 55 | 91 | 100 | 38 |
| Cost of revenue | 3 | 5 | 3 | 2 | 2 | 0 |
| Gross profit | 41 | 243 | 52 | 90 | 98 | 38 |
| Research and development | 298 | 296 | 253 | 249 | 231 | 77 |
| Selling, general and administrative | 82 | 91 | 94 | 79 | 69 | 44 |
| Operating income | (341) | (138) | (314) | (263) | (238) | (115) |
| Other non-operating income (expense) | 20 | 18 | 22 | 6 | 8 | 4 |
| Income before taxes | (321) | (120) | (292) | (254) | (218) | (57) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (321) | (120) | (292) | (254) | (218) | (57) |
| Net income | (321) | (120) | (292) | (254) | (218) | (57) |